Abstract
Specific measurement of rapid-acting insulin analogs has been complicated by lack of specificity due to structural similarity of the analogs. We
have developed novel immunoassays that specifically measure insulin
aspart (Novolog) and insulin lispro (Humalog) using new monoclonal antibodies and the Meso Scale Discovery platform.
have developed novel immunoassays that specifically measure insulin
aspart (Novolog) and insulin lispro (Humalog) using new monoclonal antibodies and the Meso Scale Discovery platform.
| Original language | American English |
|---|---|
| Article number | 1030‑P |
| Pages (from-to) | A271-A271 |
| Number of pages | 1 |
| Journal | Diabetes |
| Volume | 66 |
| Issue number | supplement 1 |
| DOIs | |
| State | Published - Jun 2017 |
Fingerprint
Dive into the research topics of 'Development of Analog-Specific Immunoassays for Pharmacokinetic Studies of Insulin Lispro and Insulin Aspart'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver